The FDA ends emergency use authorizations for Covid vaccines and issues marketing authorizations for higher-risk groups, shifting access away from younger, lower-risk populations.
The policy prioritizes higher-risk groups, reducing routine vaccinations for healthy young children under 5 while keeping options available for those who want them.
Officials frame the move as undoing extreme emergency measures and restoring a more normal, risk-based approach to vaccines and public health.